The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 ...
Lyndra Therapeutics and Thermo Fisher Scientific have entered a strategic partnership to develop Lyndra's long-acting oral ...
Shares of Thermo Fisher Scientific Inc. TMO rose 1.86% to $561.71 Thursday, on what proved to be an all-around rough trading ...
Thermo Fisher Scientific Inc. closed 8.73% below its 52-week high of $627.88, which the company reached on September 10th.
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Ameritas Advisory Services LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 19.8% during ...
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to ...
Thermo Fisher Scientific Inc (TMO) stock saw a decline, ending the day at $559.65 which represents a decrease of $-2.06 or -0.37% from the prior close of $561.71. The stock opened at $562.46 and ...
Thermo Fisher Scientific TMO +0.14% Get Free Report has outperformed the market over the past 15 years by 6.03% on an ...
As Lyndra Therapeutics works to advance long-acting oral drugs for a range of diseases, the Massachusetts-based biotech is ...
Thermo Fisher Scientific Inc (TMO) stock saw a decline, ending the day at $551.47 which represents a decrease of $-5.52 or -0.99% from the prior close of $556.99. The stock opened at $557.88 and ...
--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the UK ...